Arrow Generiques – French subsidiary of Hyderabad based Aurobindo Pharma focused on selling generic on the retail and hospital market having around 800 generic pharmaceuticals, and several brand medications has announced the signing of an agreement with Teva Pharmaceuticals subject to approval of the European Commission.
As part of this agreement, Arrow will acquire select commercial products along will the right, title and interest in products Calcium and Calcium Vitamin D3, including the use of the OROCAL trademark. Teva had acquired the product from Theramex in 2010.
Once acquired, Arrow Generiques will integrate these products with its existing commercial operations in France, and focus on maximizing their potential. This deal will boost the position of Arrow Generiques and open new opportunities for the future.
Aurobindo Pharma’s Arrow Generiques To Acquire Select Assets From Teva
Like our content? Join Capitalmind Premium.
- Equity, fixed income, macro and personal finance research
- Model equity and fixed-income portfolios
- Exclusive apps, tutorials, and member community
Subscribe Now
Or start with a free-trial
Already a subscriber?
Login Now
Related Posts
Zen Tech: Spearheading Innovation in Defence
Are defense stocks losing their shine? Has the long-term growth trend reversed? We doubt it. While stocks in this sector were down anywhere between 20-35%, we ...
Which is the best REIT in India?
As the market anticipates a potential rate cut by RBI in the near future, InvITs & REITs as an asset class are well-positioned to benefit. With that in mind, ...
Which is the best InvIT in India?
Looks like InvITs have hit a bit of a rough patch recently. But hey, every cloud has a silver lining, right? Could this dip in price be a buying opportunity? ...